MAP2K7 and cancer: Figure 5C depicts a selection of particularly strong and consistent “and/or” combinations found for clinically approved drugs. For example, in the pan-cancer dataset, the “or” combination of KRAS or BRAF improved the precision and recall compared to single predictor models to explain cell line sensitivity to a number of MEK and RAF inhibitors (e.g., Trametinib in Figures 5C and 5D).